Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
about
Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involvedA systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulationMilnacipran: a unique antidepressant?Predicting new molecular targets for known drugsThe Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary CareExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyUpdate on research and treatment of premenstrual dysphoric disorder.A prospective study of symptoms, function, and medication use during acute illness in nursing home residents: design, rationale and cohort description.Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.Tolerability and safety of fluvoxamine and other antidepressants.Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.Australian and New Zealand clinical practice guidelines for the treatment of depression.Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.Death and dependence: current controversies over the selective serotonin reuptake inhibitors.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Safety and side effect profile of fluoxetine.A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature.Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical TrialSertraline for the treatment of depression in coronary artery disease and heart failure.A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder.Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study.A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria.When the bough breaks: rethinking treatment strategies for perinatal depression.The mechanism, efficacy, and tolerability profile of agomelatine.Recognition and management of antidepressant discontinuation syndrome.Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal.A dispensing error resulting in possible fluoxetine overdose and subsequent discontinuation syndrome in a child.Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled stAntidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'.Psychotic mania in bipolar II depression related to sertraline discontinuation.Discontinuation symptoms associated with nefazodone.Re: Depression, stroke diagnosis, and SSRI discontinuation syndrome.Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?
P2860
Q21129279-2A507DF4-9135-4740-AD6C-846124207E75Q22305782-290C12E7-DE23-4DC3-B6CE-BD9719DCDC8AQ24610271-C962A0A2-BC2A-4279-B76C-DFBAE9690E90Q24649687-0A1D1AA1-D844-4107-97C9-183573FAE75BQ24682953-4D0F6064-FE14-4F5E-BD52-6B27F309429AQ28254377-F0E0AF83-5DA5-4C5E-A73B-0FFCE7BC50D5Q30475462-5CF06149-0473-4EC2-82D9-0282A1A48765Q33632706-64168E07-ED6F-4A50-A7A1-FE6DDBC3E483Q33959019-540AB6CA-6727-4A15-9D8C-81948F40C0E2Q33995120-AA1CB4B6-F2A4-423F-A6B5-04E0563798A2Q34092254-836ABA53-7A13-473E-A917-D04BE6AEEDFBQ34548787-3F6A8389-0AEF-4D04-BDEA-67092D8BBBAEQ34579202-BDD2BFDD-D851-4D9B-BD19-4A85EAD5ACE4Q35086586-3885CD8D-6EF8-49B0-9B71-D5AD2E0E6184Q35098031-045C7529-B9B7-48FC-9D3B-70B1641CD0E3Q35660695-FFAE8EC2-2D7E-4C10-8C89-4C267C62A5D7Q35862776-03D0A5C4-1ADA-41EE-BE78-C4F791225F2FQ35873740-465BDB94-795E-47AE-8152-A1F8D9094A18Q35977716-4D50AC7C-F519-4EE3-8517-116E9A641708Q36559991-E2B0594C-4171-410C-88FD-E70B142F7279Q36579331-6252105C-F94F-460D-B886-7A1FF2B2B601Q36737606-D109669B-334D-45F8-9CFC-E618C1BC82FFQ36895857-2CF9DB6E-2955-4939-A0A2-5E8396403184Q37254077-3DC199C2-A2FD-4E74-86B2-66F46254D81BQ37299884-ED75DCAB-CEC5-4254-92A5-1BB9BFA0A421Q37299893-2484C44C-4E16-42B1-B206-F74C7AE37BB6Q37562207-1ECE7D6D-6337-4195-B84C-F43642664181Q37692726-4685283D-6EB8-4D1E-86A7-7BE4B3EA6250Q38089040-AFE45023-0B5F-4A9D-84FF-661639E389F1Q38170413-9231D7B7-86B8-4544-9FF7-7A007C577F36Q41025993-EE24833F-507A-4786-A834-941FB7F83609Q41882784-A2B230F3-99BC-493C-9CE8-61535A1946C3Q43045040-AB703E57-EAD0-4A10-9402-15256487DE09Q43153951-30AE48C1-C9F3-4EA1-BB06-9C8AE88AD560Q43670028-B257E475-56F3-4233-BBFB-A30AA04138B4Q44125659-A6766CD3-5877-4F7C-B0C0-3688DE4DF0D8Q44761177-BE5848CE-EAE8-4906-9553-B1AD31F026ADQ44937617-1828FC11-E6E3-4AAE-AD04-5906EA29EBA3Q45912795-EB5D96BF-27D5-44A4-84D2-3FF8715F52E9Q46705998-10ABC349-F651-4F96-A319-97C463B6D9B0
P2860
Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Interruption of selective sero ...... ind, placebo-controlled trial.
@ast
Interruption of selective sero ...... ind, placebo-controlled trial.
@en
Interruption of selective sero ...... ind, placebo-controlled trial.
@nl
type
label
Interruption of selective sero ...... ind, placebo-controlled trial.
@ast
Interruption of selective sero ...... ind, placebo-controlled trial.
@en
Interruption of selective sero ...... ind, placebo-controlled trial.
@nl
prefLabel
Interruption of selective sero ...... ind, placebo-controlled trial.
@ast
Interruption of selective sero ...... ind, placebo-controlled trial.
@en
Interruption of selective sero ...... ind, placebo-controlled trial.
@nl
P2093
P356
P1476
Interruption of selective sero ...... ind, placebo-controlled trial.
@en
P2093
Amsterdam J
Londborg P
Michelson D
P304
P356
10.1192/BJP.176.4.363
P407
P577
2000-04-01T00:00:00Z